https://www.selleckchem.com/pr....oducts/px-478-2hcl.h
67, 95% CI 0.50-0.9. No significant advantage was registered for OS (overall survival). Indirect comparisons for safety showed an increase in terms of G3-5 AEs (with the exception of neutropenia) for mFOLFIRINOX versus gemcitabine+capecitabine (RR 1.24, 95% CI 1.03-1.5, while no significant differences were observed versus gemcitabine+nab/paclitaxel. According to our results, mFOLFIRINOX is feasible and manageable and could represent a first option for fit PC resected patients.Campylobacter jejuni causes campylobacteriosis, a ba
Like
Comment
Share
